Regeneron Pharmaceuticals (NASDAQ:REGN) said Monday that partner Hansoh Pharmaceutical Group Company Limited reported ...

Orforglipron, Eli Lilly’s oral obesity drug, is under FDA review with a decision expected in April. The pharma has also filed for marketing authorization for the pill in China.

By Andrew Silver SHANGHAI, March 6 (Reuters) - China has approved Pfizer's GLP-1 treatment Xianweiying for long-term weight ...

Ecnoglutide is distinguished by its selective activation of the cAMP signalling pathway, reducing β-arrestin recruitment.

China approves Pfizer’s GLP-1 weight-loss drug, expanding competition in the booming obesity treatment market and highlighting rising metabolic health concerns.

Military-style weight loss camps in China are getting popular. You sign up voluntarily for a month and follow a strict daily routine, with intense exercises, mandatory trips to the scales and rules on ...

Less than two weeks after Pfizer struck a deal with a Chinese drugmaker to gain commercial rights to a GLP-1 drug, the country’s National Medical Products Administration (NMPA) has ...

Eli Lilly & Co will invest $3 billion in China over the next decade to expand local production, with a focus on weight loss as the US drugmaker looks to cement its dominance in the booming obesity ...

A new, strange phenomenon called the “plastic eating” trend for weight loss is gaining momentum in China on TikTok. According to clips doing the rounds on the internet, people, especially youngsters, ...

Pfizer has claimed its first regulatory approval for a GLP-1 agonist in obesity, getting a green light in China for ecnoglutide, a once-weekly injectable drug licensed from Hangzhou-based Sciwind ...